New 2013 MMR vaccination recommendations from the CDC!
By: Reza Karimianpour.
Published on June 14th 2013, the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control & Prevention, released a change in the recommendations for measles, mumps, and rubella (MMR) vaccination based on agreements in October of 2012. These recommendations focus on prevention and post-exposure prophylaxis, in addition to recommendations for vaccination in HIV/AIDs patients. This decision was based on a study of the epidemiology of measles, mumps, and rubella cases in the United States.
New recommendations are: 
- [Removal of 'documentation of physician diagnosed disease'] as an acceptable criterion for evidence of immunity for measles and mumps, and including laboratory confirmation of disease as a criterion for acceptable evidence of immunity for measles, rubella, and mumps.
- For persons with human immunodeficiency virus (HIV) infection, expanding recommendations for vaccination to all persons aged ≥12 months with HIV infection who do not have evidence of current severe immunosuppression; recommending revaccination of persons with perinatal HIV infection who were vaccinated before establishment of effective antiretroviral therapy (ART) with 2 appropriately spaced doses of MMR vaccine once effective ART has been established; and changing the recommended timing of the 2 doses of MMR vaccine for HIV-infected persons to age 12 through 15 months and 4 through 6 years.
- For measles postexposure prophylaxis, expanding recommendations for use of immune globulin administered intramuscularly (IGIM) to include infants aged birth to 6 months exposed to measles; increasing the recommended dose of IGIM for immunocompetent persons; and recommending use of immune globulin administered intravenously (IGIV) for severely immunocompromised persons and pregnant women without evidence of measles immunity who are exposed to measles.
According to the American College of Physicians, recommendations still remain the same for children ages 12-15 months and 4-6 years, which includes two doses of MMR vaccine. High risk adults (health care personnel, college students, travelers) should receive two doses, and other adults aged 18 years or older should receive one dose. 
Disclaimer: Please note that the information above has been obtained from multiple sources for the sole purpose of student education and should not be used in the direct care of patients and/or clinical decision making.